This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

About ZEPATIER® (elbasvir and grazoprevir)

Updated on 20/02/2019

HEPATITIS C

SIMPLE* POWER TO CURE** FOR CHRONIC HEPATITIS C1-9

Simple, power to cure banner

ZEPATIER is indicated for the treatment of chronic hepatitis C genotypes 1 and 4 infection in adults1

ZEPATIER 12 weeks achieved 95% SVR for treatment naïve patients’ image

*“simple” is supported by the information held on the DDIs and dosing simplicity page

**Cure of HCV infection = sustained virologic response (SVR), the primary endpoint in all studies, was defined as hepatitis C virus (HCV) ribonucleic acid (RNA) less than the lower limit of quantification (LLOQ) (=15 IU/ml) at 12 weeks after the cessation of treatment.1,11

Related content

Does not meet the search condition data (0 results)
 

References

  1. ZEPATIER summary of Product Characteristics.
  2. Dore GL et al, Ann Int Med 2016;doi:10.7326/M16-0816 [Epub ahead of print]
  3. Roth D et al. Lancet 2015:386:1537-1545.
  4. Rockstroh JK et al. Lancet HIV 2015:2(8);319-327.
  5. Zeuzem S et al. Ann Intern Med 2015; 163:1-13.
  6. Forns X et al. J Hepatol 2015;63:564-572.
  7. Kwo PY et al. C-EDGE TE EASL 2015.
  8. Sperl J et al. Presented at EASL April 13-17 2016; Barcelona Spain: Abstract PS002.
  9. Jacobson IM et al. Presented at: 66th Annual Meeting of the American Association for the Study of Liver Diseases; November 13-17 2015; Boston, MA.
  10. Europena Association for the Study of the Liver. J Hepatol 2015;63:199-236.

Supporting documentation

Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-ZEP-00052 | Date of Preparation: February 2019